Samsung outlines blockbuster investment plan for biopharmaceuticals, part of a $22B play on next-gen tech
After building up a biosimilars group and branching out into new drug development, Samsung says it plans to make a big push on the biopharmaceuticals front over the next three years, lining up $22 billion to make this one of several growth areas for the conglomerate.
There aren’t a lot of details to go with this. Samsung — under pressure from Chinese rivals — broadly said that it’s ready to wager $22 billion on next-gen technologies, noting a big interest in AI, auto electronics and biopharma, according to the Financial Times.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.